Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma

Inclusion Criteria

• Inpatients or outpatients, ≥ 18 years of age
• Histologically confirmed primary (non-recurrent) ESCC fulfilling one of the following criteria (AJCC Staging System)
• cervical esophageal carcinoma, stage Ⅱ-Ⅲ
• upper thoracic esophageal carcinoma, stage Ⅱ-Ⅲ, or mid-thoracic esophageal carcinoma, stage Ⅱ-Ⅲ,which is medically unfit for surgery, surgery been refused and patient medically able to tolerate chemo-radiation.
• Evidence of unidimensional measurable disease as per Response Evaluation Criteria in Solid Tumours (RECIST).
• ECOG Performance status of 0-1
• Effective contraception for both male and female patients if the risk of conception exists
• Adequate bone marrow reserves: neutrophil (ANC) count ≥ 1500 /mm^3, platelet count ≥ 100,000 /mm^3, hemoglobin ≥ 9 g/dl
• Adequate renal function: serum creatinine ≤ 1.5 mg/dl and/or calculated creatinine clearance ≥ 60 ml/min
• Adequate hepatic function: bilirubin level ≤ 1.5 x ULN, ASAT & ALST ≤ 1.5 x ULN
• Tumor tissue available for KRAS biomarker test
• Signed written informed consent prior to study entry

Exclusion Criteria

• Previous chest radiotherapy, systemic chemotherapy, and major esophageal surgery
• Concurrent chronic systemic immune therapy, targeted therapy not indicated in this study protocol
• Multiple primary carcinomas of the esophagus
• Pregnancy (confirmed by serum or urine β-HCG) or lactation period;
• Uncontrolled diabetes, hypertension, and severe cardiac or pulmonary disease
• Unable to comprehend the study requirements or who are not likely to comply with the study parameters;
• Distant metastasis
• Second malignancy, except for curable non-melanoma skin cancer, cervical cancer in situ, or malignant disease, free for ≥ 5 years
• Known grade 3 or 4 allergic reaction to any of the study treatment